Cediranib (CAS: 288383-20-0)

Appearance

Cediranib is a yellowish crystalline powder.

Properties

Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.

Beginning in 2007, it underwent Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other medicine used in cancer treatment were also undertaken.

On February 27, 2008, AstraZeneca announced that the use of Cediranib in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. On 8 March 2010, AstraZeneca issued a press-release stating that Cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader bevacizumab. As of November 2012, it was being assessed in double-blind studies for the treatment of methylated Glioblastoma Multiforme at the University of Washington Medical Center at a 20 mg daily dose.

Combination Trials

Findings from a federally funded, NCI-sponsored phase II clinical trial presented at the 50th Annual Meeting of the American Society of Clinical Oncology (May 30 – June 3, 2014, Chicago, Ill; Abstract No: LBA5500), show that the combination of two investigational oral medicine, olaparib (AZD-2281; AstraZeneca) , a potential first-in-class poly ADP ribose polymerase or PARP inhibitor and cediranib, an anti-angiogenesis drug, is significantly more active against recurrent, platinum chemotherapy-sensitive disease or ovarian cancer related to mutations in BRCA genes than olaparib alone.

Hazards Identification 

Adverse Effects: Adverse effects of vaginal application may include vaginal burning, itching, 

discharge or other irritation;abdominal cramps or pain; and headache. Possible allergic 

reaction to material if inhaled, ingested or in contact with skin. 

Overdose Effects: n/f 

Acute: Possible eye, skin, gastrointestinal and/or respiratory tract irritation. 

Chronic: Possible hypersensitization. 

Inhalation: May cause irritation. Remove to fresh air. 

Eye: May cause irritation. Flush with copious quantities of water. 

Skin: May cause irritation. Flush with copious quantities of water. 

Ingestion: May cause irritation. Flush out mouth with water. 

Medical Conditions Aggravated by Exposure: Hypersensitivity to material. 

Cross Sensitivity: Persons sensitive to azole antifungal agents may be sensitive to this material 

also. 

Pregnancy Comments: Adequate and well-controlled pregnancy studies in humans have not 

been done. In studies in rats, adverse effects on fetal development and delivery were observed 

during local and systemic use.